NCT01186705终止2 期
A Phase II Clinical And Translational Study Of MK-2206 In Patients With Metastatic KRAS-Wild-Type, PIK3CA-Mutated, Colorectal Cancer
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 终止
- 入组人数
- 1
- 试验地点
- 1
- 主要终点
- Overall Objective Response Rate (ORR)
研究概览
简要总结
The purpose of this study is to test a new drug called MK-2206 for metastatic colorectal cancer. This drug is being tested in a subgroup of patients with colorectal cancer whose tumors have changes in certain genes that may make them more likely to respond to this new medication. As tumors develop, the cells within the tumor acquire mutations within genes, allowing them to grow more effectively. We will be testing your tumor for mutations involving two genes - KRAS and PIK3CA. Patients whose tumors have a normal copy of the KRAS gene and a mutation within the PIK3CA gene will be eligible to participate in this study.
This study is a phase 2 study. The goal of a phase 2 study is to find out what effects, good and/or bad, a new treatment has against a certain type of cancer.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patient must have metastatic colorectal cancer that has been histologically or cytologically-confirmed at MSKCC and has failed to respond to appropriate standard therapy regimens. There is no limit on the number of prior treatment regimens permitted.
- •Patient is male or female and ≥18 years of age on the day of signing informed consent.
- •Patient must have performance status of 0 or 1 on the ECOG Performance Scale.
- •Patient must have adequate organ function as indicated by the following laboratory values:
- •Absolute neutrophil count (ANC) ≥1,500 /μL
- •Platelets ≥100,000 /μL
- •Hemoglobin ≥9 g/dL
- •Serum creatinine or calculated creatinine clearance ≤1.5 x upper limit of normal (ULN) OR ≥60 mL/min for patients with creatinine levels >1.5 x institutional ULN
- •Serum total bilirubin ≤1.5 x ULN OR direct bilirubin ≤ ULN for patients with total bilirubin levels >1.5 x ULN
- •AST (SGOT) and ALT (SGPT) ≤3 x ULN or ≤5 x ULN in patients with known liver metastasis
- •Prothrombin time (PT)/INR ≤1.5 x ULN
- •Partial thromboplastin time (PTT)≤1.5 x ULN
- •Fasting serum glucose ≤120 mg/dl
- •HBA1C ≤8%
- •Potassium in normal range
- •The patient has a tumor that has wild type KRAS (absence of mutations at codons 12 or 13), and mutant PIK3CA (presence of mutations in exons 20 or 9).
- •Female patient of childbearing potential who are not surgically sterilized must have a negative serum or urine pregnancy test β-hCG within 72 hours prior to receiving the first dose of study medication.
- •Patient, or the patient's legal representative, has voluntarily agreed to participate by giving written informed consent.
- •Patient is able to swallow capsules and has no surgical or anatomical condition that will preclude the patient from swallowing and absorbing oral medications on an ongoing basis.
排除标准
- •Patient who has had chemotherapy, radiotherapy, or biological therapy within 3 weeks (6 weeks for nitrosoureas or mitomycin C), or who has not recovered from the adverse events due to previous agents administered more than 4 weeks prior to Study Day
- •If the patient has residual toxicity from prior treatment, toxicity must be ≤ Grade
- •Patients must be at least 4 weeks post major surgical procedure, and all surgical wounds must be fully healed.
- •Patient is currently participating or has participated in a study with an investigational compound or device within 30 days of Study Day
- •Patient has known CNS metastases and/or carcinomatous meningitis.
- •Patient has a primary central nervous system tumor.
- •Patient has known hypersensitivity to the components of study drug or its analogs.
- •Patient has a history or current evidence of clinically significant heart disease including:
- •Clinically significant congestive heart failure, unstable angina pectoris,
- •Clinically significant cardiac arrhythmia,
- •History or current evidence of a myocardial infarction during the last 6 months, and/or a current ECG tracing that is abnormal in the opinion of the treating Investigator,
- •QTc prolongation ≥450 msec (Bazett's Formula), Patient with evidence of clinically significant bradycardia (HR <50), or a history of clinically significant bradyarrhythmias such as sick sinus syndrome, 2nd degree AV block (Mobitz Type 2).
- •Patient with uncontrolled hypertension (i.e., > 160/90 mHg SiBP). Patients who are controlled on antihypertensive medication will be allowed to enter the study.
- •Patient at significant risk for hypokalemia (e.g., patients on high dose diuretics, or with recurrent diarrhea)
- •Patient with poorly controlled diabetes (HBA1C >8%)
- •Patient has a history or current evidence of any condition, therapy, or lab abnormality that might confound the results of the study, interfere with the patient's participation for the full duration of the study, or is not in the best interest of the patient to participate, in the opinion of the treating Investigator.
- •Patient has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial
- •Patient is, at the time of signing informed consent, a regular user (including -recreational use‖) of any illicit drugs or had a recent history (within the last year) of drug or alcohol abuse.
- •Patient is breastfeeding or expecting to conceive or father children within the projected duration of the study.
- •Patient is known to be Human Immunodeficiency Virus (HIV)-positive
- •Patient has known history of Hepatitis B or C or active Hepatitis A.
- •Patient has symptomatic ascites or pleural effusion. A patient who is clinically stable following treatment for these conditions is eligible.
- •Patient is receiving treatment with oral corticosteroids (note: inhaled corticosteroids are permitted).
研究组 & 干预措施
MK-2206
Experimental
This will be a single-arm, phase II study of the AKT inhibitor MK-2206 in patients with KRAS-wild-type, PIK3CA-mutated, colorectal cancer whose tumors have progressed through standard chemotherapy regimens.
干预措施: MK-2206 (Drug)
结局指标
主要结局
Overall Objective Response Rate (ORR)
时间窗: 1 year
in patients with metastatic colorectal cancer with known PIK3CA mutations and wild type KRAS, to single agent MK-2206. Response and progression will be evaluated in this study using the new international criteria proposed by the Response Evaluation Criteria in Solid Tumors (RECIST) (version 1.1)
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
已完成
2 期
Study of MK-2206 in Patients With Metastatic Neuroendocrine Tumors (NET)PANCREASNeuroendocrineNCT01169649Memorial Sloan Kettering Cancer Center11
撤回
2 期
MK-2206 for Recurrent Malignant GliomaMalignant GliomaNCT01249105Dana-Farber Cancer Institute
进行中（未招募）
2 期
The Efficacy and Safety of HLX208 in Metastatic Colorectal Cancer (mCRC) With BRAF V600E MutationMetastatic Colorectal CancermCRCNCT05127759Shanghai Henlius Biotech25
已完成
2 期
Akt Inhibitor MK2206 in Treating Patients With Advanced Gastric or Gastroesophageal Junction CancerAdenocarcinoma of the Gastroesophageal JunctionDiffuse Gastric AdenocarcinomaGastric Intestinal Type AdenocarcinomaGastric Mixed AdenocarcinomaRecurrent Gastric CarcinomaNCT01260701National Cancer Institute (NCI)75
终止
2 期
MK2206 in Treating Patients With Advanced Liver Cancer That Did Not Respond to Previous TherapyAdult Hepatocellular CarcinomaAdvanced Adult Hepatocellular CarcinomaLocalized Non-Resectable Adult Liver CarcinomaRecurrent Adult Liver CarcinomaNCT01239355National Cancer Institute (NCI)15